Condition
EBV-associated Tumors
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Not Yet Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT07349836Early Phase 1Not Yet RecruitingPrimary
Application of mRNA Immunotherapy Technology in EB Virus Related Diseases
NCT07101536Not ApplicableNot Yet RecruitingPrimary
The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)
Showing all 2 trials